Abstract:G-protein-coupled receptors (GPCRs, also called seven-transmembrane or heptahelical receptors) are a superfamily of cell surface receptor proteins that bind to many extracellular ligands and transmit signals to an intracellular guanine nucleotide-binding protein (G-protein). When a ligand binds, the receptor activates the attached G-protein by causing the exchange of Guanosine-5'-triphosphate (GTP) for guanosine diphosphate (GDP). They play a major role in many physiological functions, as well as in the pathology of many diseases, including cancer progression and metastasis. Only a few GPCR members have been exploited as targets for developing drugs with therapeutic benefit in cancer. Present review briefly summarizes the signaling pathways utilized by the EP (prostaglandin E receptor) family of GPCR, their physiological and pathological roles in carcinogenesis, with special emphasis on the roles of EP4 in breast cancer progression. We make a case for EP4 as a promising newer therapeutic target for treating breast cancer. We show that an aberrant over-expression of cyclooxygenase (COX)-2, which is an inflammation-associated enzyme, occurring in 40-50% of breast cancer patients leads to tumor progression and metastasis due to multiple cellular events resulting from an increased prostaglandin (PG) E2 production in the tumor milieu. They include inactivation of host anti-tumor immune cells, such as Natural Killer (NK) and T cells, increased immuno-suppressor function of tumor-associated macrophages, promotion of tumor cell migration, invasiveness and tumor-associated angiogenesis, due to upregulation of multiple angiogenic factors including Vascular Endothelial Growth Factor (VEGF)-A, increased lymphangiogenesis (due to upregulation of VEGF-C/D), and a stimulation of stem-like cell (SLC) phenotype in cancer cells. All of these events were primarily mediated by activation of the Prostaglandin (PG) E receptor EP4 on tumor or host cells. We show that selective EP4 antagonists (EP4A) could mitigate all of these events tested with cells in vitro as well as in vivo in syngeneic COX-2 expressing mammary cancer bearing mice or immune-deficient mice bearing COX-2 over-expressing human breast cancer xenografts. We suggest that EP4A can avoid thrombo-embolic side effects of long term use of COX-2 inhibitors by sparing cardio-protective roles of PGI2 via IP receptor activation or PGE2 via EP3 receptor activation. Furthermore, we identified two COX-2/EP4 induced oncogenic and SLC-stimulating microRNAs-miR526b and miR655, one of which (miR655) appears to be a potential blood biomarker in breast cancer patients for monitoring SLC-ablative therapies, such as with EP4A. We suggest that EP4A will likely produce the highest benefit in aggressive breast cancers, such as COX-2 expressing triple-negative breast cancers, when combined with other newer agents, such as inhibitors of programmed cell death (PD)-1 or PD-L1.

Prostaglandin E Receptor 4 (EP4) Promotes Colonic Tumorigenesis

Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment

Host And Direct Antitumor Effects And Profound Reduction In Tumor Metastasis With Selective Ep4 Receptor Antagonism

Prostaglandin E-2 Promotes Colorectal Adenoma Growth Via Transactivation Of The Nuclear Peroxisome Proliferator-Activated Receptor Delta

Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy

Role of Prostaglandin Receptor EP2 in the Regulations of Cancer Cell Proliferation, Invasion, and Inflammation

CXCL1 Induced by Prostaglandin E2 Promotes Angiogenesis in Colorectal Cancer.

Prostaglandin E-2 Enhances Intestinal Adenoma Growth Via Activation of the Ras-Mitogen-Activated Protein Kinase Cascade

Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions

Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression

Inhibitory effects of a selective prostaglandin E2 receptor antagonist RQ-15986 on inflammation-related colon tumorigenesis in APC-mutant rats

PDE4 and Epac1 Synergistically Promote Rectal Carcinoma Via the Camp Pathway.

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines.

Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer.

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

The G protein-coupled P2Y₆ receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis

EP4 as a Therapeutic Target for Aggressive Human Breast Cancer

EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells

Granulin Epithelin Precursor Promotes Colorectal Carcinogenesis by Activating MARK/ERK Pathway

Prostaglandin E2 (PGE2) Promotes Proliferation and Invasion by Enhancing SUMO-1 Activity Via EP4 Receptor in Endometrial Cancer.